Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer.
Improved Aptamers for the Diagnosis and Potential Treatment of HER2-Positive Cancer.
复制标题
DOI：
10.3390/ph9020029
复制
发表时间：
2016-05-19
期刊：
影响因子：
--
通讯作者：
Aerts AM
中科院分区：
文献类型：
--
作者：
Gijs M;Penner G;Blackler GB;Impens NR;Baatout S;Luxen A;Aerts AM
适配体为现有的抗体诊断和治疗提供了替代靶向分子的潜在来源。在这项工作中，我们通过贴壁全细胞SELEX方法选择了靶向HER2受体的新型DNA适体。通过下一代测序和生物信息学分析鉴定了个体适体。两个适体HeA2_1和HeA2_3与HER2蛋白结合的亲和力在纳摩尔范围内。此外，这两种适体都能以高特异性与her2过表达细胞和her2阳性肿瘤组织样本结合。此外，我们证明了适体HeA2_3被内化到癌细胞中，并对癌细胞的生长和生存有抑制作用。最后，我们选择了具有诊断和治疗her2阳性癌症潜力的新型DNA适体。
Aptamers provide a potential source of alternative targeting molecules for existing antibody diagnostics and therapeutics. In this work, we selected novel DNA aptamers targeting the HER2 receptor by an adherent whole-cell SELEX approach. Individual aptamers were identified by next generation sequencing and bioinformatics analysis. Two aptamers, HeA2_1 and HeA2_3, were shown to bind the HER2 protein with affinities in the nanomolar range. In addition, both aptamers were able to bind with high specificity to HER2-overexpressing cells and HER2-positive tumor tissue samples. Furthermore, we demonstrated that aptamer HeA2_3 is being internalized into cancer cells and has an inhibitory effect on cancer cell growth and viability. In the end, we selected novel DNA aptamers with great potential for the diagnosis and possible treatment of HER2-positive cancer.